Background: An important cause of coagulopathy in cardiac surgery is impaired thrombin generation. While plasma is often used to correct this element of the coagulopathy, studies in vitro suggest that prothrombin complex concentrates (PCCs) might be more effective. Comparative data, however, are scant. Methods: We compared the outcomes of those who received only plasma with those who received PCCs (with or without plasma) for management of coagulopathy in patients who underwent cardiac surgery with cardiopulmonary bypass at a single institution from 2012 to 2016. Propensity score matching was used to obtain between-group balance. Primary outcome was avoidance of perioperative red cell transfusions. Other outcomes were incidence of massive transfusion (more than nine red cell units), refractory bleeding (requiring factor VIIa), and adverse events. Results: Of 6362 patients, 1151 (18.2%) received plasma without any PCCs, and 204 (3.2%) received PCCs, either with (n¼125) or without plasma (n¼79). Overall, patient risk-profile was higher in the PCCs group. In a well-balanced propensity score match that included 117 patients per group, the odds ratio (OR) for red cell avoidance was 2.4-fold [95% confidence interval (CI) 1.2e4.8] higher in the PCCs group. Massive transfusion (OR 0.58; 95% CI 0.33e1.0) and refractory bleeding (OR 0.49; 95% CI 0.24e1.03) incidences were almost significantly lower in the PCCs group. The adverse event profiles were similar. Conclusions: Our exploratory study suggests that the use of PCCs as part of a multifaceted coagulation management strategy may have blood-sparing effects. Their incorporation into clinical practice, however, must await determination of their risk-benefit profile via multicentre randomised trials.
Cardiac surgery requiring the use of cardiopulmonary bypass (CPB) is frequently complicated by coagulopathy that can lead to excessive haemorrhage and blood transfusions, potentially worsening patients' prognosis. 1e3 As the causes of coagulopathy are often multifactorial, clinicians use an array of therapies to control the haemorrhage, including antifibrinolytics to inhibit fibrinolysis, platelet transfusions to treat thrombocytopenia and platelet dysfunction, cryoprecipitate or fibrinogen concentrate to increase fibrinogen concentrations, and frozen plasma or prothrombin complex concentrate (PCC) to replenish depleted clotting factors and to improve thrombin generation. 1, 4 Concerning the latter, impaired thrombin generation is increasingly recognised to be an important contributor to the coagulopathy of cardiac surgery. 5, 6 While plasma may effectively restore thrombin generation and is an integral part of transfusion algorithms, 4, 7 it has important shortcomings. 8 It requires ABO blood group compatibility matching and thawing, which can delay therapy. It can also lead to adverse events including allergic reactions, transfusion-related acute lung injury (TRALI), transfusion associated circulatory overload (TACO), transmission of infectious diseases, and thromboembolic events. 8, 9 Moreover, as large volumes (10e15 ml kg À1 )
of plasma are needed to effectively raise thrombin generation, 7 it can lead to substantial haemodilution resulting in additional red cell transfusions. PCCs, which are purified products that are prepared from plasma and contain the procoagulant factors II, VII, IX, and X, the anticoagulant proteins C and S, and small amounts of heparin, 4 have several potential advantages to plasma. Unlike plasma, they do not require ABO compatibility matching or thawing, and have a substantially lower risk for TRALI and TACO. 9 Moreover, in vitro studies suggest that PCCs may be more effective than plasma in enhancing thrombin generation after cardiac surgery. 7 In contrast, as PCCs do not contain the full, balanced complement of procoagulants and anticoagulants that are present in plasma, they may be less effective or carry a higher risk for thrombotic events and acute kidney injury (AKI) than plasma for management of coagulopathy. 10, 11 Despite the potential advantages of PCCs over plasma, there are few direct comparisons between the two therapies for managing the coagulopathy of cardiac surgery. Nevertheless, at our institution, PCC is being increasingly used to supplement or supplant plasma in bleeding cardiac surgical patients, providing us with a cohort of patients who received PCC, plasma, or both during their surgery. Using this cohort, we conducted this retrospective observational study to compare the outcomes of patients who received only plasma with those who received PCCs with or without additional plasma as part of their coagulation management, using propensity score matching to control for important betweengroup imbalances. We hypothesised that the use of PCC would be associated with reduced transfusion needs and massive transfusion without increasing the risk of thromboembolic complications and AKI.
Methods
This was a retrospective observational study that included data collected on cardiac surgery patients operated from January 1, 2012 to December 30, 2016 at the Toronto General Hospital, a teaching hospital affiliated with the University of Toronto (Toronto, ON, Canada). A full range of adult cardiac surgical procedures are performed at this hospital. After approval from the institutional research ethics board, which waived the need for informed consent, patient data were obtained from institutional databases. We included all patients who underwent cardiac surgery with CPB, but excluded those in whom transfusion data were missing. For patients who had multiple operations requiring CPB during the study period, only data from their first surgery were used. Full-time research personnel blinded to the objectives of this study adjudicated all outcomes from patients' records.
Clinical practice
Clinical practice has been previously described. 12 CPB circuits were phosphorylcholine coated and the typical prime included 1000 ml of crystalloid (with mannitol and heparin added). Anticoagulation for CPB was achieved with a heparin bolus of 400 IU kg À1 with additional doses as required to maintain the activated clotting time >480 s. During CPB, shed pericardial blood was salvaged into the cardiotomy suction reservoir and re-infused via the CPB circuit for as long as patients were anticoagulated. Heparin was reversed with protamine (1 mg per 100 IU of the initial bolus of heparin). Cell salvage was available for all patients and was used to recover lost blood before and after anticoagulation at the discretion of the clinical team. Tranexamic acid (various dosing strategies but typical total dose was 50e100 mg kg
À1
) was routinely administered to patients if there were no absolute contraindications. Institutional allogeneic red cell transfusion criteria included a haemoglobin <7 g dl À1 during CPB, <8 g dl À1 post-CPB, and <9 g dl À1 in unstable or bleeding patients. Autologous red cell pre-donation was not used. Management of post-CPB coagulopathy was guided by a combination of whole-blood point-of-care assays (viscoelastic and platelet function measures, performed when temperature reached 36 C at the end of CPB) and standard laboratory assays (complete blood count, prothrombin time, international normalised ratio (INR), partial thromboplastin time, and fibrinogen concentration performed soon after protamine administration), as previously described. 13 
Outcomes
The primary outcome was avoidance of perioperative (day of or day after surgery) red cell transfusions. Other outcomes were incidence of massive transfusion (!10 units of red cells day of or day after surgery), incidence of rescue therapy with recombinant activated factor VII (which at our institution is used as a last resort in patients with refractory bleeding), 2 and avoidance of other blood products (platelets, cryoprecipitate, or fibrinogen concentrate). Transfusion outcomes include pre-, intra-, and postoperative transfusions. The primary safety outcome was the incidence of AKI, defined based on the consensus recommendations of the AKI Network (AKIN) for serum creatinine criteria, measured from before surgery to the highest creatinine concentration on postoperative calendar days 1 or 2 (corresponding to AKIN's 48-h time constraint). 15 Increase in creatinine of !26.4 mmol litre À1 or 1.5e2.0 fold was Class I, >2.0e3.0 fold was Class II, >3.0 fold or in-hospital renal replacement therapy was Class III. Patients who were on renal replacement therapy before surgery were excluded from this analysis. Other safety outcomes analysed were in-hospital death, stroke (evidence of a persistent neurological deficit), and deep vein thrombosis or pulmonary embolism (required radiological confirmation).
Statistical analysis
Patients were categorised into two groups: those who received only plasma (FP group) or those who received PCC with or without plasma (PCC group). Categorical variables were summarised as frequencies (%) and continuous variables as medians [inter-quartile range (IQR)] unless otherwise stated. The c 2 or Fisher's exact c 2 and Wilcoxon two-sample tests were used to compare patient characteristics, risk status, and outcomes between the FP and PCC groups. Propensity score methods 16e18 were used to obtain between-group balance with respect to measured confounders and predictors of measured outcomes (Table 1) , and year of surgery. To accomplish this, the propensity score for receiving PCC was first derived for all patients by multivariable logistic regression modelling that included any variable that the groups were not balanced on [defined as a standardised mean difference (SMD), which is the absolute difference of the group means as a percentage of their pooled standard deviation, of >10%]. 16 Patients were then matched based on their propensity scores, using a 5/1 computerised greedymatching technique. 19 The quality of the match was assessed by re-calculating each variable's SMD in the matched sample. If balance (SMD 10%) 16 was not achieved for a variable that was not included in the original model, then it was added to the model and the matching was repeated. If balance was not achieved for variables that were already in the model, the cross-product of that variable with other clinically related variables was included in subsequent models. This iterative process was repeated until the best balance for important confounders was achieved. 20 Once the model was finalised, outcomes of interest were compared between the matched groups using conditional logistic regression and Wilcoxon signed-rank test. 18 Several variables not available in the entire dataset (baseline platelet count, preoperative warfarin use, and dose of tranexamic acid, heparin, and protamine, and cell salvage blood returned) were retrospectively obtained from the records of matched patients. The characteristics of the matched group were also compared with the unmatched group to explore differences between matched and unmatched patients. Lowest haemoglobin concentrations on postoperative days 2e7 were compared between the groups to explore postoperative red cell transfusion thresholds.
The sample size was one of convenience. SAS TM version 9.4
(SAS Institute, Cary, NC, USA) was used for the analyses.
Results
During the study period, 6362 patients underwent cardiac surgery with CPB, 48 of whom were excluded because of missing transfusion data. Of the remaining 6314 patients, 4959 (78.5%) received neither plasma nor PCC, 1151 (18.2%) received plasma without any PCC, and 204 (3.2%) received PCC, either with or without plasma (n¼125 and 79; respectively). The former was considered the FP group and the latter the PCC group. The FP group received four (two, six) units of plasma and the PCC group received 2000 (1000, 2000) IU of PCC plus four (zero, six) units of plasma perioperatively. Overall, patient risk-profile was higher in the PCC group, as they had more comorbidities such as shock, left ventricular dysfunction, and renal dysfunction, and more frequently underwent complex, urgent procedures requiring longer CPB durations ( Table 1) .
The final propensity score derivation model used for matching included 20 main-effects variables and one crossproduct variable. Propensity score matching resulted in 117 matched pairs that were balanced on measured confounders (Table 1) . Importantly, balance was achieved on post-CPB INR, platelet count, and plasma equivalents transfused, indicating that severity of coagulopathy was comparable in the matched group (Table 1) . While the post-CPB haemoglobin was lower in the FP group (Table 1) , the small difference indicates that perioperative red cell transfusion practice was similar in the two groups. Of note, the lowest haemoglobin on postoperative days 2e7 was similar between the groups: 7.7 (7.2, 8.4) g dl À1 in the FP group and 7.7 (7.2, 8.5) g dl À1 in the PCC group.
As for variables not included in the propensity score model, the groups were balanced on preoperative platelet count, cell salvage blood returned, and dose of tranexamic acid and heparin, but the dose of protamine was slightly higher in the plasma group (Table 1) . On the use of warfarin, 24 (20.5%) patients in the plasma group and 32 (27.4%) in the PCC group received warfarin before surgery (P¼0.3), but in all except 11 patients who underwent emergency surgery, it was discontinued at least 3 days before surgery.
The matched FP group received six (two, nine) units of plasma and zero (zero, zero) IU of PCC, and the matched PCC group received two (zero, four) units of plasma and 2000 (1000, 2000) IU of PCC perioperatively. Units of perioperative red cell transfusions were four (two, nine) in the FP group and three (one, seven) in the PCC group (P¼0.02) and for platelets they were two (one, four) and two (one, three) units (P¼0.29), respectively. In the matched group, the odds of perioperative and in-hospital red cell avoidance were 2.4-fold (95% confidence interval 1.2e4.8) higher in the PCC group. Massive transfusion and refractory bleeding incidences were lower in the PCC group (Table 2) . Other outcomes, including transfusion of other blood products and adverse events, were similar between the two groups ( Table 2) .
Of the 204 patients who received PCCs, a suitable match could not be identified in 87 of them. In 18 patients, propensity scores could not be obtained because of missing values. In the remaining 69, the average propensity score was substantially 
Discussion
In this retrospective, single-centre observational study, we found that, in a well-balanced match of 117 patients who received PCC to supplement or supplant plasma and 117 patients who received only plasma for management of coagulopathy during cardiac surgery, PCC use was associated with a 2.4-fold increase in the odds of red cell transfusion avoidance. Massive transfusion and refractory bleeding incidences tended to be lower in the PCC group, while the adverse event profiles were similar. As noted earlier, coagulopathy after cardiac surgery is multifactorial, but impaired thrombin generation resulting from a combination of CPB-associated haemodilution, surgical blood loss, and the promotion of tissue factor pathway inhibitor by heparin is thought to be an important contributor. 5 In an in vitro study, PCC was found to be more potent in restoring post-CPB thrombin generation than plasma. 7 This may in part explain why the use of PCC as part of a multifaceted management of coagulopathy seems to have a greater blood-sparing effects than plasma. Supportive clinical data, however, is limited. In a small observational study, Arnekian and colleagues 21 compared three groups of cardiac surgical patients: 24 who received only PCC, 26 who received only plasma, and 27 who received both products. In an unadjusted analysis, they found that red cell transfusions were lowest in the PCC group and highest in the combination group. However, given the small sample size and lack of risk-adjusted analysis, few conclusions can be drawn from this study. In another study that included only patients who underwent pulmonary endarterectomy, Ortmann and colleagues 22 compared transfusions and outcomes between 55 patients who received only plasma and 45 patients who received only PCC for management of post-CPB coagulopathic bleeding. In an unadjusted analysis, they found that the PCC group had lower blood loss than the plasma group, but transfusion rates were similar. They conducted multivariable regression analysis for adverse events, and found no differences between the two groups. Given its small sample size, limited generalisability, and lack of riskadjustment for efficacy outcomes, however, few conclusions can be drawn from this study. In a larger study, Cappabianca and colleagues 23 used propensity scores to match 225 patients who received a three-factor (factors II, IX, and X) PCC (with or without plasma) to 225 patients who received only plasma for management of post-CPB coagulopathy. They found red cell transfusions were lower in the PCC group (84% vs 93%; P¼0.002), as were multiple (more than two units) red cell transfusions (51% vs 70%; P<0.0001) and amount of red cell transfusions (3.4 vs 5.2 units; P<0.0001). Moreover, while there were no major between-group differences in adverse outcomes, in a regression analysis that incorporated the propensity score they found an association between PCC use and AKI that led them to caution about this potential risk. The efficacy findings of this study are consistent with ours, but we did not find an association between PCC use and AKI (but we used a shorter time-frame for the diagnosis of AKI). Importantly, Cappabianca and colleagues 23 did not observe an association of PCC use with AKI in their propensity score matched group analysis, which may be a better type of analysis because it provides a more transparent comparison of treatment effect than regression analysis. 24 Our study had several important limitations. First, because it was a retrospective, observational study, it can only identify associations and cannot prove cause-and-effect relationships. Second, as the study was not randomised, the PCC and FP groups had major differences in terms of important confounders, which necessitated propensity score matching to obtain balanced groups for comparisons. Even though the matched groups were balanced on measured confounders, it is possible that they differed in potentially important unmeasured confounders that accounted for observed associations. Third, we could not obtain a suitable match for a large number of PCC patients who represented a high-risk group of patients. Moreover, this was a relatively small study, there were few thromboembolic events, and the study was conducted at a single hospital where PCC use was based on evolving indications and the clinical judgment of attending anaesthesiologists. Thus, the study has limited generalisability, was underpowered to illustrate safety, and may be predisposed to exaggerated treatment effects. 25 In conclusion, our exploratory study suggests that the use of PCC as part of a multifaceted coagulation management strategy for post-CPB coagulopathy may have blood-sparing effects. Given that evidence to date is limited to experimental and non-randomised trials, however, multicentre randomised controlled clinical trials equipped to determine the risk-benefit profile of PCC for this indication are needed before their use is incorporated into routine clinical practice. Declaration of interest K.K. and J.C. have received research support and honoraria from Octapharma. K.K. is supported in part by a merit award from the Department of Anesthesia, University of Toronto. J.C. has received research support from the Canadian Blood Services. Otherwise, none of the authors have any affiliations with or involvement in any organisation or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.
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